Stocks to Watch: HCLTech, Infosys, Tata Motors, Paytm, Maruti, Religare, and Others
Stocks to Watch: HCLTech, Infosys, Tata Motors, Paytm, Maruti, Religare, and Others
Stocks to watch: Shares of firms like HCLTech, Infosys, Tata Motors, Paytm, Maruti, Religare, and others will be in focus on Thursday's trade.

Stocks To Watch On October 13: GIFT Nifty on the NSE IX traded 18 points, or 0.09 per cent, higher at 19,693, signaling that Dalal Street was headed for positive start on Friday. Here’s a slew of stocks that will be in focus today for various reasons.

HCLTech: The company has revised its FY24 revenue guidance to 5-6 per cent in constant currency terms from the earlier estimate of 6-8 per cent.

HCLTech reported a 9 per cent YoY increase in its net profit to Rs 3,833 crore.

IDBI Bank: The RBI is expected to accelerate a key process of vetting IDBI Bank’s potential buyers and complete it by October end in what would speed upits divestment process, reported Reuters.

Religare Enterprises: The market regulator Sebi is studying the Burman family’s open offer to acquire additional 26 per cent in Religare Enterprises and has sought additional information from the company, a news report stated.

Tata Motors: Jaguar Land Rover (JLR) India reported sales of 2,356 units for April-September, from around 1,194 units in the same period last year.

Maruti Suzuki: The company that its board will meet on October 17 to consider issuing preference shares to parent Suzuki Motor Corp SMC instead of a cash consideration to acquire Suzuki Motor Gujarat.

Paytm: The RBI has imposed a monetary penalty of Rs 5.39 crore on Paytm Payments Bank for violating Know Your Customer norms, among others.

Mphasis: The company’s arm will acquire US-based Sonnick Partners for $132.5 million. Sonnick Partners (Silverline) is a digital transformation consultancy & salesforce partner.

Dr Reddy’s: The US FDA has issued the company Form 483 with nine observations for its Bachupally unit in Hyderabad.

Panacea Biotec: The US FDA issued Form 483 with nine observations for its Baddi unit.

Lupin: The company has received US FDA approval for the generic equivalent of Xywav Oral Solution, made by Ireland’s Jazz Pharmaceuticals.

IRB Infra Trust: The company has executed definitive agreements to implement the Samakhiyali Santalpur BOT project in Gujarat. The trust will acquire a 99.96 per cent stake in STPL for a total consideration of Rs 116.2 crore. The total project cost is Rs 2,092 crore.

What's your reaction?

Comments

https://rawisda.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!